Court rules companies can't import Gilead medications from overseas in blow to AFP health programs
A U.S. appeals court has ruled in favor of Gilead Sciences against companies known as alternative funding programs that import medicines from overseas.
A U.S. appeals court has ruled in favor of Gilead Sciences against companies known as alternative funding programs that import medicines from overseas. This story matters for Finance & Markets readers tracking fund. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. FundNews curates and briefs the finance & markets stories that matter. Our editorial policy →